疤痕零(ScarZero)
皮肤老化过程在角质层主要表现为角质层细胞粘连性增加,角质层堆积过多,使皮肤显得灰暗,失去亮丽的光泽,使之出现皱纹。因此,维持正常的角质层是保持皮肤美丽的关键。
我们直接接触到的皮肤外层就是角质层,位于表皮最上层,由5~20层已经死亡的扁平细胞构成,这一层的细胞时刻处于脱落——移行的动态平衡中,但由于各种外因导致角质层时常处于以下状态:
脱落过度——干燥,脆弱易敏感;
脱落不足——晦暗发黄,粗糙,无生气的外观;
脱落不均匀——干燥起皮。更多阅读
纳米脂质体包裹羟基酪醇(橄榄叶提取物),NanoLiposomal Hydroxytyrosol
CAS:10597-60-1
产品类别:抗衰老、抗皱,抗氧化、自由基清除剂,美白祛斑,抗皱
产品描述:天然橄榄中的羟基酪醇具有卓越的抗氧化活性,氧化自由基吸收能力是维生素C的30倍。纳米脂质体包裹羟基酪醇,极大提升了羟基酪醇的稳定性和易用性,充分发挥出清除自由基的功效,修复氧化损伤,焕发肌肤细胞活力。羟基酪醇作为新一代的抗衰成分,也是现在正大热的抗衰美白成分,它是一种天然多酚类化合物,具有多种生物和药理活性。不仅应用于心血管药物的合成,更是作为安全高效的抗氧剂,应用于美容产品保健品,具除皱抗衰老之功效。更多阅读
白转黑®Grey2Dark®
INCI名称:迷迭香提取物、羟丙基四氢吡喃三醇、生物类黄酮、乙酰基酪氨酸、棕榈酰寡肽、磷脂、己二醇、甘油、水
第一缕银丝让我们很难接受,因为它们会显著影响感知年龄。白发的产生是由于发干中没有颜色,毛囊中黑色素生成减少。由于人口老龄化的加剧和青少年少白头的现象,治疗白发的产品有着巨大的市场需求。
虾青素-强大的抗氧化剂
虾青素,又名虾黄质、龙虾壳色素,是一种类胡萝卜素,也是类胡萝卜素合成的最高级别产物,呈深粉红色,化学结构类似于β-胡萝卜素。而β – 胡萝卜素、叶黄素、角黄素、番茄红素等都是类胡萝卜素合成的中间产物,因此在自然界,虾青素具有最强的抗氧化性。更多阅读
PR-4 雌二醇透皮凝胶
PR-4(estradiol topical nanoemulsion) is designed to deliver estradiol to the blood circulation following topical application of an nanoemulsion.Estradiol is intended for the treatment of moderate to severe vasomotor symptoms associated with menopause.
PR-3 环孢菌素
PR-3 is a novel ciclosporin nanoemulsion eye drops intended for the treatment of severe keratitis in adult patients with dry eye disease (DED).The active substance of PR-3 is ciclosporin, an immunosuppressant belonging to the therapeutic class of ophtalmologicals. Ciclosporin blocks the release of pro-inflammatory cytokines and exerts an anti-inflammatory effect in ocular surface cells.
PR-2 双氯芬酸胶囊
PR-2 is a novel formulation of diclofenac prepared by nanoemulsion drug delivery system.Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for management of mild to moderate acute pain and osteoarthritis (OA) pain.
PR-1 注射用多西他赛脂质体 Liposomal Docetaxel
PR-1 is a novel nanoparticle formulation of docetaxel (Taxotere), a drug widely used in the treatment of a variety of solid tumor types.The American Cancer Society estimates that 1.6 million new cases of cancer will be reported in the US in 2012, and that 577,000 people will die as a result of this disease. Cancer is the second most common cause of death after heart disease, accounting for nearly one in four deaths. Taxotere generated worldwide revenue of ~$2.7B (€2.1) in 2010. A unique opportunity exists for this novel formulation of docetaxel to capture significant market share based on its improved safety, tolerability and efficacy profile over docetaxel (Taxotere).